# A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Staphylococcal Investigational Vaccine in Healthy Adults

> **NCT01160172** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 88 (actual)

## Conditions studied

- Infections, Staphylococcal

## Interventions

- **BIOLOGICAL:** Staphylococcal investigational vaccine GSK2392103A
- **BIOLOGICAL:** Staphylococcal investigational vaccine GSK2392105A
- **BIOLOGICAL:** Staphylococcal investigational vaccine GSK2392106A
- **BIOLOGICAL:** Staphylococcal investigational vaccine GSK2392019A
- **DRUG:** Saline placebo

## Key facts

- **NCT ID:** NCT01160172
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07-19
- **Primary completion:** 2012-08-23
- **Final completion:** 2012-08-23
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2017-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01160172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01160172, "A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Staphylococcal Investigational Vaccine in Healthy Adults". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT01160172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*